Cargando…
Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics
BACKGROUND: Prekallikrein activator (PKA) is a contaminating enzyme found in therapeutic albumin and immunoglobulin products. The level is commonly measured using methods such as that defined by the European Pharmacopoeia (Ph Eur) with traceability to the WHO International Standard for PKA. This met...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891625/ https://www.ncbi.nlm.nih.gov/pubmed/32986885 http://dx.doi.org/10.1111/vox.12980 |
_version_ | 1783652738367750144 |
---|---|
author | Roberts, Graham Fox, Bernard Longstaff, Colin |
author_facet | Roberts, Graham Fox, Bernard Longstaff, Colin |
author_sort | Roberts, Graham |
collection | PubMed |
description | BACKGROUND: Prekallikrein activator (PKA) is a contaminating enzyme found in therapeutic albumin and immunoglobulin products. The level is commonly measured using methods such as that defined by the European Pharmacopoeia (Ph Eur) with traceability to the WHO International Standard for PKA. This method generally works well, but problems are sometimes observed. MATERIALS AND METHODS: A simplified one‐step method has been developed to replace the existing Ph Eur two‐step method which consists of kallikrein generation followed by kallikrein measurement using a chromogenic substrate. Analysis of data from the one‐stage method is simplified by the use of a dedicated online app. RESULTS: The one‐stage method was validated against the current Ph Eur method using batches of albumin and immunoglobulins. Problem batches of immunoglobulins were investigated using the one‐stage method. Improved methodology using true initial rate determinations and use of acid‐treated prekallikrein substrate (PKS) helped understand and reduce artefactual results. CONCLUSIONS: The one‐stage method and associated app streamline real‐time determination of PKA and promote good principles of enzyme assays to limit substrate depletion, while also conserving expensive PKS. Blanking steps and reproducibility are simplified. |
format | Online Article Text |
id | pubmed-7891625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78916252021-03-02 Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics Roberts, Graham Fox, Bernard Longstaff, Colin Vox Sang Original Papers BACKGROUND: Prekallikrein activator (PKA) is a contaminating enzyme found in therapeutic albumin and immunoglobulin products. The level is commonly measured using methods such as that defined by the European Pharmacopoeia (Ph Eur) with traceability to the WHO International Standard for PKA. This method generally works well, but problems are sometimes observed. MATERIALS AND METHODS: A simplified one‐step method has been developed to replace the existing Ph Eur two‐step method which consists of kallikrein generation followed by kallikrein measurement using a chromogenic substrate. Analysis of data from the one‐stage method is simplified by the use of a dedicated online app. RESULTS: The one‐stage method was validated against the current Ph Eur method using batches of albumin and immunoglobulins. Problem batches of immunoglobulins were investigated using the one‐stage method. Improved methodology using true initial rate determinations and use of acid‐treated prekallikrein substrate (PKS) helped understand and reduce artefactual results. CONCLUSIONS: The one‐stage method and associated app streamline real‐time determination of PKA and promote good principles of enzyme assays to limit substrate depletion, while also conserving expensive PKS. Blanking steps and reproducibility are simplified. John Wiley and Sons Inc. 2020-09-28 2021-01 /pmc/articles/PMC7891625/ /pubmed/32986885 http://dx.doi.org/10.1111/vox.12980 Text en © 2020 Crown copyright. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion. This article is published with the permission of the controller of HMSO and the Queen’s Printer for Scotland. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Papers Roberts, Graham Fox, Bernard Longstaff, Colin Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics |
title | Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics |
title_full | Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics |
title_fullStr | Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics |
title_full_unstemmed | Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics |
title_short | Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics |
title_sort | development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891625/ https://www.ncbi.nlm.nih.gov/pubmed/32986885 http://dx.doi.org/10.1111/vox.12980 |
work_keys_str_mv | AT robertsgraham developmentofanupdatedassayforprekallikreinactivatorinalbuminandimmunoglobulintherapeutics AT foxbernard developmentofanupdatedassayforprekallikreinactivatorinalbuminandimmunoglobulintherapeutics AT longstaffcolin developmentofanupdatedassayforprekallikreinactivatorinalbuminandimmunoglobulintherapeutics |